Cipher Pharmaceuticals

218 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Announces Canadian Launch of Brinavess (vernakalant hydrochloride)

  10/24/2018

  Brinavess® (vernakalant hydrochloride) is for the rapid conversion of recent onset atrial fibrillation

• Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis

  9/18/2018

  Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market

• Cipher Pharmaceuticals Reports Q2 2018 Results

  8/10/2018

  Canadian product revenue increased 33%

• Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica

  7/30/2018

  New portfolio royalty extends through December 2024

• Notice of Cipher Pharmaceuticals Q2 2018 Conference Call

  7/23/2018

  Cipher Pharmaceuticals Inc. announced the details of its Q2 2018 financial results conference call on Friday, August 10, 2018.

• Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs

  6/6/2018

  Dr. Gajewczyk has more than 25 years of pharmaceutical industry experience in the research, clinical development and commercialization of pharmaceutical, biologics, vaccine and medical device products.

• Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.

  5/16/2018

  Effective May 15, 2018, the previously announced acquisition by Cipher Pharmaceuticals Inc. ("Cipher") of the Canadian business portfolio of Cardiome Pharma Corp. was completed.

• Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma

  5/15/2018

  Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has completed its previously announced acquisition of Cardiome Pharma Corp.

• Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

  5/15/2018

  Cardiome Pharma Corp. Becomes Correvio Pharma Corp., Closes on $25.5 million (CAD) in Non-Dilutive Capital

• Cipher Pharmaceuticals Reports Voting Results for the Election of Directors

  5/11/2018

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced today the voting results for the election of directors at its Annual and Special Meeting of Shareholders held on May 10, 2018 in Toronto, Ontario.

• Cipher Pharmaceuticals Reports Q1 2018 Results

  5/10/2018

  Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2018.

• Notice of Cipher Pharmaceuticals Q1 2018 Conference Call & Annual Meeting

  5/1/2018

  Cipher Pharmaceuticals Inc. announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on Thursday, May 10, 2018.

• Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors

  4/26/2018

  Dr. Rulleau is currently a partner at CTI Life Sciences

• Cipher Pharmaceuticals Provides Corporate Update and Preliminary Q1 2018 Revenue Results

  4/23/2018

  Cipher announced four transactions that demonstrate meaningful progress in the execution of its growth strategy to assemble a diversified portfolio of prescription products that will deliver reliable growth for shareholders.

• Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics

  4/6/2018

  Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratosis.

• Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

  3/20/2018

  Cipher Pharmaceuticals and Cardiome Pharma Corp. announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome.

• Cipher Pharmaceuticals Reports Q4 & FY2017 Results

  2/28/2018

  90% increase in revenue and 214% increase in income from continuing operations for Q4 2017

• Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE from Synergy Pharmaceuticals

  2/28/2018

  TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.

• Cipher Pharma Comments On Supply Chain Impact From Hurricane Maria

  10/10/2017

• Cipher Pharma Comments On FDA Warning Letter For ConZip (Tramadol)

  9/7/2017